Javascript must be enabled to continue!
Cost effectiveness analysis comparing varying booster intervals of vaccination policies to address COVID-19 situation in Thailand, 2023
View through CrossRef
The COVID-19 booster immunization policy is cost-effective, but evidence on additional booster doses and appropriate strategies is scarce. This research compared the cost-effectiveness of annual, twice-a-year, and biennial booster dose policies. We performed stochastic modeling using compartmental susceptible-exposed-infectious-recovered models and a system dynamic model. We evaluated four policy scenarios: (1) hypothetical no-booster immunization policy; (2) twice-a-year vaccination policy; (3) annual vaccination policy; and (4) biennial vaccination policy. In addition, we conducted a one-way sensitivity analysis by adjusting R0 from 1.8 to 3.0 in all scenarios (epidemic stage) and by decreasing the vaccination cost by 50% at the end of the first year to reflect the current policy direction to enhance domestic vaccine production. Compared to non-booster policies, all three booster strategies reduced the number of cases, hospital admissions, and severe infections remarkably. Without a booster, total cases would reach 16,220,615 (95% confidence interval [CI] 6,726,550–29,661,112) by day 1,460, whereas, with a twice-a-year booster, the total cases would reach 597,901 (95% CI 526,230–694,458) in the same period. Even though the no booster scenario exhibited the lowest cost by approximately the first 500 days, by day 1,460 the biennial booster scenario demonstrated the lowest cost at 72.0 billion baht (95% CI 68.6–79.4 billion). The most cost-saving policy was the biennial booster scenario. The annual booster scenario also stood as a cost-effective option for most outcomes. In the epidemic stage and in an assumption where the vaccination costs dropped, all booster policies became more cost-effective or cost-saving compared with the main assumption. This study underscores the significance of the COVID-19 vaccine booster policy. Implementing policies should take into consideration cost-effectiveness, feasibility, and public communication.
Public Library of Science (PLoS)
Title: Cost effectiveness analysis comparing varying booster intervals of vaccination policies to address COVID-19 situation in Thailand, 2023
Description:
The COVID-19 booster immunization policy is cost-effective, but evidence on additional booster doses and appropriate strategies is scarce.
This research compared the cost-effectiveness of annual, twice-a-year, and biennial booster dose policies.
We performed stochastic modeling using compartmental susceptible-exposed-infectious-recovered models and a system dynamic model.
We evaluated four policy scenarios: (1) hypothetical no-booster immunization policy; (2) twice-a-year vaccination policy; (3) annual vaccination policy; and (4) biennial vaccination policy.
In addition, we conducted a one-way sensitivity analysis by adjusting R0 from 1.
8 to 3.
0 in all scenarios (epidemic stage) and by decreasing the vaccination cost by 50% at the end of the first year to reflect the current policy direction to enhance domestic vaccine production.
Compared to non-booster policies, all three booster strategies reduced the number of cases, hospital admissions, and severe infections remarkably.
Without a booster, total cases would reach 16,220,615 (95% confidence interval [CI] 6,726,550–29,661,112) by day 1,460, whereas, with a twice-a-year booster, the total cases would reach 597,901 (95% CI 526,230–694,458) in the same period.
Even though the no booster scenario exhibited the lowest cost by approximately the first 500 days, by day 1,460 the biennial booster scenario demonstrated the lowest cost at 72.
0 billion baht (95% CI 68.
6–79.
4 billion).
The most cost-saving policy was the biennial booster scenario.
The annual booster scenario also stood as a cost-effective option for most outcomes.
In the epidemic stage and in an assumption where the vaccination costs dropped, all booster policies became more cost-effective or cost-saving compared with the main assumption.
This study underscores the significance of the COVID-19 vaccine booster policy.
Implementing policies should take into consideration cost-effectiveness, feasibility, and public communication.
Related Results
Vaccination is reasonably effective in limiting the spread of COVID-19 infections, hospitalizations and deaths with COVID-19
Vaccination is reasonably effective in limiting the spread of COVID-19 infections, hospitalizations and deaths with COVID-19
Abstract
This paper uses large cross-country data for 110 countries to examine the effectiveness of COVID vaccination coverage. Our results confirm that vaccines ar...
Cost-Effectiveness Analysis of COVID-19 Vaccine Booster Dose in the Thai Setting during the Period of Omicron Variant Predominance
Cost-Effectiveness Analysis of COVID-19 Vaccine Booster Dose in the Thai Setting during the Period of Omicron Variant Predominance
The Thai government implemented COVID-19 booster vaccines to prevent morbidity and mortality during the spreading of the Omicron variant. However, little is known about which types...
COVID-19 Booster Vaccine Hesitancy among Hemodialysis Patients in Saudi Arabia Using the Health Belief Model: A Multi-Centre Experience
COVID-19 Booster Vaccine Hesitancy among Hemodialysis Patients in Saudi Arabia Using the Health Belief Model: A Multi-Centre Experience
Objective: Vaccination hesitance for the COVID-19 booster dosage among hemodialysis patients is an important barrier in reducing morbidity and mortality linked to COVID-19 infectio...
Additional COVID-19 Booster Vaccine Hesitancy Among Healthcare Workers in a Private Teaching Hospital in Hong Kong
Additional COVID-19 Booster Vaccine Hesitancy Among Healthcare Workers in a Private Teaching Hospital in Hong Kong
Abstract
Introduction: The emergence of new coronavirus variants during the COVID-19 pandemic necessitates the consideration of additional booster vaccinations for high-ris...
Acceptance of COVID-19 Booster in the adult population of Pakistan: A cross sectional study
Acceptance of COVID-19 Booster in the adult population of Pakistan: A cross sectional study
Abstract
Background: A year after the COVID-19 pandemic vaccination rollout, vaccine elicited immunity is waning and newer variants e.g. The Delta Variants and Omicron have...
Abstract P2-20-01: Safety and Clinical Efficacy of Multiple Booster Inoculations with the E75 Adjuvant Breast Cancer Vaccine
Abstract P2-20-01: Safety and Clinical Efficacy of Multiple Booster Inoculations with the E75 Adjuvant Breast Cancer Vaccine
Abstract
Background: We are conducting clinical trials of the HER2/neu E75-peptide+GM-CSF vaccine in clinically disease-free breast cancer patients at high risk for ...
Second Booster Vaccine and Covid-19 Mortality in Adults 60 to 100 Years Old
Second Booster Vaccine and Covid-19 Mortality in Adults 60 to 100 Years Old
Abstract
The rapid emergence of the B.1.1.529 (omicron) variant of severe acute respiratory syndrome coronavirus-2 led to a global resurgence of coronavirus disease 2019 (C...

